Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 18, 2021

Cara Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2021

Cara Therapeutics Reports Third Quarter 2021 Financial Results

GlobeNewswire November 8, 2021

Cara Therapeutics Announces CEO Transition

GlobeNewswire November 3, 2021

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

GlobeNewswire November 1, 2021

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA(TM)) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

GlobeNewswire October 4, 2021

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

GlobeNewswire September 29, 2021

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

GlobeNewswire September 24, 2021

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA(TM) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Business Wire August 24, 2021

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA(TM) (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

GlobeNewswire August 23, 2021

Cara Therapeutics Reports Second Quarter 2021 Financial Results

GlobeNewswire August 9, 2021

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

GlobeNewswire August 2, 2021

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics

PR Newswire June 11, 2021

Cara Therapeutics to Present at the Jefferies Healthcare Conference

GlobeNewswire May 25, 2021

Cara Therapeutics Reports First Quarter 2021 Financial Results

GlobeNewswire May 10, 2021

Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

GlobeNewswire May 6, 2021

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

GlobeNewswire May 3, 2021

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA(TM) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

GlobeNewswire April 29, 2021

Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

GlobeNewswire April 7, 2021

Cara Therapeutics Set to Join S&P SmallCap 600

PR Newswire April 5, 2021